Article

RNAi in arthritis: prospects of a future antisense therapy in inflammation.

Inserm U 844, INM Hôpital Saint Eloi, BP 74103, 80 rue Augustin Fliche, 34091 Montpellier cedex 5, France.
Current opinion in molecular therapeutics (impact factor: 3.68). 11/2007; 9(5):483-9. pp.483-9
Source: PubMed

ABSTRACT Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.

0 0
 · 
0 Bookmarks
 · 
22 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

chronic autoimmune disease
 
chronic systemic inflammation
 
clinical treatments
 
control gene expression
 
experimental arthritic models
 
first successful attempts
 
remarkable new research tool
 
Rheumatoid arthritis
 
rheumatoid disorders
 
RNAi
 
RNAi-based therapy
 
systemic delivery
 
TNFalpha
 
unknown etiology